Acta Scientific Medical Sciences (ISSN: 2582-0931)

Perspective Volume 4 Issue 6

Verisiguat: A New Kid in Town. But One Size does not Fit all Heart Failure

Dimitris J Richter*

Head of Cardiac Department, Euroclinic Hospital, Athens, Greece

*Corresponding Author: Head of Cardiac Department, Euroclinic Hospital, Athens, Greece

Received: March 29, 2020; Published: May 31, 2020

×

Leaving in the Corona-virus era, brings a lot of digital innovations including the first LBCT presentation virtually. The Victoria [1] study presented virtually at ACC 2020 and published simultaneously at NEJM presented the results of verisiguat, a novel oral soluble guanylate cyclase stimulator, that enhances the cyclic guanosine monophosphate (GMP) pathway by directly stimulating soluble guanylate cyclase through a binding site independent of nitric oxide, and it sensitizes soluble guanylate cyclase to endogenous nitric oxide by stabilizing nitric oxide binding to the binding site [2].

×

Citation

Citation: Dimitris J Richter. “Verisiguat: A New Kid in Town. But One Size does not Fit all Heart Failure". Acta Scientific Medical Sciences 4.6 (2020): 145-146.



Member In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US